OncoMatch/Clinical Trials/NCT07022002
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Is NCT07022002 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including SSGJ-705 and PD-1/L1 inhibitor combined with chemotherapy for locally advanced, recurrent or metastatic malignancies.
Treatment: SSGJ-705 · PD-1/L1 inhibitor combined with chemotherapy · SSGJ-705 combined with chemotherapy — This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: HER2 (ERBB2) overexpression
HER2-Expressing
Disease stage
Metastatic disease required
local advanced or metastatic
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Inadequate organ or bone marrow function [excluded]
Kidney function
Inadequate organ or bone marrow function [excluded]
Liver function
Inadequate organ or bone marrow function [excluded]
Inadequate organ or bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify